Patents by Inventor Zhigang Weng

Zhigang Weng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240166734
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Application
    Filed: June 16, 2023
    Publication date: May 23, 2024
    Inventors: Lorena LERNER, Sandra ABBOTT, Ailin BAI, Ting CHEN, Maria Isabel CHIU, Qing LIU, Laura POLING, Nianjun TAO, Solly WEILER, Zhigang WENG, William M. WINSTON, JR., Jeno GYURIS
  • Patent number: 11725047
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: August 15, 2023
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • Publication number: 20210101968
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Application
    Filed: March 19, 2020
    Publication date: April 8, 2021
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, JR., Jeno Gyuris
  • Patent number: 10597444
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: March 24, 2020
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria I. Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • Publication number: 20180142013
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Application
    Filed: July 20, 2017
    Publication date: May 24, 2018
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria I. Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • Patent number: 9725505
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: August 8, 2017
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria I. Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • Publication number: 20160083465
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 24, 2016
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria I. Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, JR., Jeno Gyuris
  • Patent number: 9175076
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: November 3, 2015
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • Publication number: 20140193427
    Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 10, 2014
    Applicant: AVEO PHARMACEUTICALS, INC.
    Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
  • Publication number: 20130288305
    Abstract: Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.
    Type: Application
    Filed: June 5, 2013
    Publication date: October 31, 2013
    Inventors: Zhigang Weng, William M. Winston, JR., Ailin Bai, Kristan Meetze, Solly Weiler, Ting Chen, Jeno Gyuris
  • Patent number: 8481688
    Abstract: Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: July 9, 2013
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Zhigang Weng, William M. Winston, Jr., Ailin Bai, Kristan Meetze, Solly Weiler, Ting Chen, Jeno Gyuris
  • Patent number: 8187601
    Abstract: Monoclonal antibodies that bind and inhibit activation of fibroblast growth factor receptor 3 (FGFR3) are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of FGFR3.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: May 29, 2012
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Zhigang Weng, William M. Winston, Jr., Lyne Breault, Kristan Meetze, Solly Weiler, Jeno Gyuris
  • Publication number: 20110305687
    Abstract: Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.
    Type: Application
    Filed: May 11, 2011
    Publication date: December 15, 2011
    Inventors: Zhigang Weng, William M. Winston, JR., Ailin Bai, Kristan Meetze, Solly Weiler, Ting Chen, Jeno Gyuris
  • Publication number: 20100003258
    Abstract: Monoclonal antibodies that bind and inhibit activation of fibroblast growth factor receptor 3 (FGFR3) are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of FGFR3.
    Type: Application
    Filed: June 30, 2009
    Publication date: January 7, 2010
    Inventors: Zhigang Weng, William M. Winston, JR., Lyne Breault, Kristan Meetze, Solly Weiler, Jeno Gyuris
  • Publication number: 20060198789
    Abstract: An method of determining whether a gene of interest is necessary for a tumor cell to maintain its tumorigenicity is disclosed. The method is useful for validation of cancer therapeutic targets in vivo, using shRNAs and tumor xenografts. The inducible shRNA method operates an in vivo RNAi competition assay.
    Type: Application
    Filed: January 6, 2006
    Publication date: September 7, 2006
    Inventors: Zhigang Weng, Jeno Gyuris, Steven Clark
  • Patent number: 6709830
    Abstract: The invention provided herein describes ligands and methods for modulating a G protein-coupled receptor (GPCR), designated G2A, a lymphocyte expressed receptor whose genetic ablation results in the development of autoimmunity. The present disclosure teaches that lysophosphatidylcholine (LPC) is a high affinity ligand for G2A and that sphingosylphosphorylcholine (SPC) is a lower affinity ligand for G2A. As G2A activation is shown to be involved in a variety of physiological processes including cell proliferation, autoimmunity and inflammation, methods which modulate its activity have a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: March 23, 2004
    Assignee: The Regents of the University of California
    Inventors: Owen N. Witte, Zhigang Weng, Lu Q. Le, Janusz H. S. Kabarowski, Yan Xu, Kui Zhu
  • Patent number: 6569995
    Abstract: A G protein-coupled receptor (GPCR) which is activated by oncogenes. The receptor is found predominantly in hematopoietic cells and tissues and functions as a tumor suppressor gene and induces cell cycle arrest. This receptor may play an important role in regulating the proliferation and differentiation of hematopoietic cells. Regulation of receptor activity has several therapeutic applications.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: May 27, 2003
    Assignee: The Regents of the University of California
    Inventors: Zhigang Weng, Owen N. Witte
  • Patent number: 6514696
    Abstract: A G protien-coupled receptor (GPCR), called G2A, whose expression is regulated and functions at the G2/M checkpoint to ensure properly controlled duplication of hematopietic cells. The receptor is found predominantly in hematopietic cells and tissues and functions as a tumor suppressor gene, induces cell cycle arrest and integrates diverse signals by modulation of cytoskeletal architecture.
    Type: Grant
    Filed: April 20, 2000
    Date of Patent: February 4, 2003
    Assignee: The Regents of The University of California
    Inventors: Zhigang Weng, Owen N. Witte
  • Patent number: 6383760
    Abstract: A G protein-coupled receptor (GPCR), called G2A, whose expression is regulated and functions at the G2/M checkpoint to ensure properly controlled duplication of hematopoietic cells. The receptor is found predominantly in hematopoietic cells and tissues and functions as a tumor suppressor gene and induces cell cycle arrest. This receptor may play an important role in regulating the proliferation and differentiation of hematopoietic cells. Regulation of receptor activity has several therapeutic applications.
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: May 7, 2002
    Assignee: The Regents of the University of California
    Inventors: Zhigang Weng, Owen N. Witte
  • Publication number: 20020051980
    Abstract: The invention provided herein describes ligands and methods for modulating a G protein-coupled receptor (GPCR), designated G2A, a lymphocyte expressed receptor whose genetic ablation results in the development of autoimmunity. The present disclosure teaches that lysophosphatidylcholine (LPC) is a high affinity ligand for G2A and that sphingosylphosphorylcholine (SPC) is a lower affinity ligand for G2A. As G2A activation is shown to be involved in a variety of physiological processes including cell proliferation, autoimmunity and inflammation, methods which modulate its activity have a variety of diagnostic and therapeutic applications.
    Type: Application
    Filed: February 28, 2001
    Publication date: May 2, 2002
    Applicant: The Regents of the University of California
    Inventors: Owen N. Witte, Zhigang Weng, Lu Q. Le, Janusz H.S. Kabarowski, Yan Xu, Kui Zhu